Story perspectives

FDA Panel Reviews Seven Peptide Drugs Amid Safety Concerns

7/1/2026

Summary

FDA Panel Reviews Peptides

The FDA’s Pharmacy Compounding Advisory Committee will meet July 23-24 to decide on seven peptides, a move supported by Health Secretary Robert F. Kennedy Jr.
FDA staff reviewers said safety and effectiveness evidence is limited and warned of immunogenicity, heavy-metal, microbial contamination, and no human trials.
The panel, which includes industry-linked members Melissa Loseke and Gabriel Alizaidy, faces criticism from former member Dr. Anita Gupta and orthopedist Alexander Weber for lacking data.

Summary

FDA Considers Peptides

The FDA will hold an advisory meeting before the end of February 2027 to consider five more peptides.
Peptide sellers, including Dr. Gabriel Alizaidy and clinic operator Haleem Mohammed in Florida, label products “for research use only,” promote BPC-157 and GHK-Cu online, charge $500 per consultation, and sell unapproved injections with vitamins.
Tennessee senator Bobby Harshbarger was praised by President Donald Trump, whose pardon of Harshbarger’s father followed a drug-substitution conviction.

1 of 2

FDA Panel Reviews Peptides

The FDA’s Pharmacy Compounding Advisory Committee will meet July 23-24 to decide on seven peptides, a move supported by Health Secretary Robert F. Kennedy Jr.
FDA staff reviewers said safety and effectiveness evidence is limited and warned of immunogenicity, heavy-metal, microbial contamination, and no human trials.
The panel, which includes industry-linked members Melissa Loseke and Gabriel Alizaidy, faces criticism from former member Dr. Anita Gupta and orthopedist Alexander Weber for lacking data.

1 / 2